Takeda Pharmaceutical (TAK) Capital Expenditures (2018 - 2026)

Takeda Pharmaceutical has reported Capital Expenditures for 9 years, with the latest figure at -$337.6 million in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 1.95% year-over-year to -$337.6 million in Q2 2026; TTM through Jun 2026 was -$1.2 billion, a 8.08% increase from a year earlier, with the FY2026 full-year figure at -$1.1 billion, up 14.86% from the prior year.
• Capital Expenditures was -$337.6 million for Q2 2026 at Takeda Pharmaceutical, down from -$295.6 million in the prior quarter.
• The five-year high for Capital Expenditures was -$212.1 million in Q3 2022, with the low at -$369.0 million in Q2 2024.
• Average Capital Expenditures over 5 years is -$299.5 million, with a median of -$303.3 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures advanced 24.09% in 2022, then slumped 34.46% in 2023.
• Over 5 years, Capital Expenditures stood at -$236.9 million in 2022, then plunged by 34.46% to -$318.5 million in 2023, then advanced by 6.88% to -$296.6 million in 2024, then rose by 8.78% to -$270.5 million in 2025, then decreased by 24.8% to -$337.6 million in 2026.
• The last three Capital Expenditures figures came in at -$337.6 million (Q2 2026), -$295.6 million (Q1 2026), and -$270.5 million (Q4 2025), per Business Quant data.